Dr Matthias Magoola, the founder and managing director of Dei Biopharma Ltd, has been awarded one of the continent’s top honours—the 2025 African Excellence & Personality Award (ACEPA)—for his groundbreaking work in biotechnology and pharmaceuticals.
The award ceremony, held on April 25 in Accra, Ghana, placed a spotlight not only on scientific innovation but also on African self-reliance in health care. For Dr Magoola, a soft-spoken but driven scientist and entrepreneur, the recognition comes on the heels of other international accolades.
In recent months alone, he has been honoured at the 2025 Ratna Pharma Awards in India for his contributions to vaccine research and at the prestigious International Molecular Biologist Awards, where he was named Best Researcher of the Year in December 2024 for his cutting-edge work in mRNA-based therapeutic drugs and vaccines.
But the ACEPA award, presented by the ACEPA Secretariat in Ghana, carries a uniquely pan-African weight. The organisers praised Dr Magoola for “his visionary leadership and groundbreaking innovations in sectors vital to Africa’s progress, particularly economic development and healthcare transformation.”
His work, they said, has set a new benchmark for African solutions to African problems—especially in the pharmaceutical sector, long dependent on imports and external aid.
“Dr Magoola’s commitment to advancing biotechnology and pharmaceuticals has established a new standard for self-reliance within Africa’s healthcare sector,” the award organisers stated.
A LOCAL VISION WITH GLOBAL AMBITION
At the heart of this recognition is Dei Biopharma Ltd, the company Dr. Magoola founded and nurtured into Uganda’s most ambitious biotechnology firm. Headquartered in Kampala and now building a multi-billion-dollar drug and vaccine manufacturing plant in Matugga, Dei Biopharma is positioning itself as a central player in Africa’s future pharmaceutical landscape.
Beyond manufacturing, the company is also at the forefront of medical innovation. Dei Biopharma has filed over 100 patents with the United States Patent and Trademark Office (USPTO), covering treatments and vaccines for conditions as complex and deadly as cancer, HIV/Aids, Alzheimer’s, sickle cell anaemia, malaria, tuberculosis, and diabetes.
One of the most promising recent developments is a novel cancer treatment based on guided mRNA. Published by the USPTO in February 2025, the invention uses mrna-based therapy to target and disrupt mutated genes responsible for cancer—a technology that could redefine oncology in low-resource settings.
Earlier this year, the USPTO also accepted an application for what could become the world’s first universal vaccine for foot and mouth disease (FMD)—a devastating livestock infection that has long plagued Ugandan and African farmers.
The invention, titled “Affordable Universal Fusion Vaccine for Foot and Mouth Disease Infections”, is being hailed as a potential game-changer in agricultural health and food security.
“This vaccine will save the government billions of shillings that have been going into imports,” Dr Magoola said. “It’s a homegrown solution to a persistent challenge.”
PRESIDENTIAL SUPPORT FOR A NATIONAL MISSION
Magoola’s rise has not gone unnoticed by Uganda’s leadership. Just weeks before the Ghana award, he met with President Yoweri Museveni at State House Entebbe. The meeting, held on April 13, focused on fast-tracking vaccine licensing and regulatory reform to allow Ugandan-made products to reach global markets.
President Museveni pledged to support the passage of the National Drug and Health Products Act, a key legal reform that would help Uganda’s National Drug Authority (NDA) secure World Health Organization (WHO) Maturity Level 3 accreditation.
This would allow Uganda to license and export locally produced vaccines—turning Uganda from a buyer into a supplier on the global stage.
“We are grateful for the support from the government, and especially His Excellency President Yoweri Museveni,” Dr. Magoola said.
“Without his unwavering support, these milestones would not have been possible. These achievements belong to Uganda—and specifically to our president, who has always stood by the scientists of this country.”
INNOVATION ROOTED IN PURPOSE
At its core, Dr Magoola’s journey is not just about science—it’s about impact. Whether it’s offering an affordable cancer treatment, disrupting dependency on imported vaccines, or training the next generation of Ugandan researchers, his vision is as inclusive as it is ambitious.
His work also signals a shift in how science is valued in Uganda. Long seen as the preserve of external donors and international labs, biomedical innovation is now being nurtured from within—by Ugandans, for Ugandans, and for the continent.
As Uganda continues its journey toward middle-income status, the importance of homegrown innovation has never been clearer. In a country where healthcare access and affordability remain uneven, scientific leadership like Dr. Magoola’s may be one of the surest paths to closing the gap.